Overview
The main hypothesis of the study is that in situ infiltration of the meniscal lesion would provide patients with lasting and greater relief than intra-articular infiltration. A statistically significant difference would be if the Lysholm score of the meniscal wall group at 3 months is 9.5 points higher than that of the intra-articular infiltration group.
The aim is to evaluate the effectiveness of meniscal wall infiltration under ultrasound in the treatment of stable degenerative meniscal lesions versus intra-articular infiltration (Gold standard) at 3 months by Lysholm's algo-functional score.
Eligibility
Inclusion Criteria:
- Patients with a symptomatic meniscal lesion of a degenerative nature, isolated or associated with early osteoarthritis or chondropathy (Ahlbach stages 1 and 2).
- Indication for peri-meniscal infiltration under ultrasound control of the knee for a clinically stable degenerative meniscal lesion confirmed by MRI and radiography.
- Patient who has given free and informed consent.
- Patient who has signed the consent form.
- Patient affiliated or beneficiary of a health insurance plan.
- Adult patient (≥18 years of age).
Exclusion Criteria:
- No iconographic evidence of meniscal injury.
- Associated lesions of the central pivot of the knee.
- Knee pain of osteoarthritic origin strongly suggested by the clinic associated with an advanced radiological stage of osteoarthritis (Ahlbach stages 3 and 4).
- Presence of a skin lesion at the infiltration sites.
- Suspected soft tissue or joint infection.
- Patient participating in research involving human subjects defined as Category 1.
- Patient in an exclusion period as determined by another study.
- Patient under court protection, guardianship or trusteeship.
- Patient unable to give consent.
- Patient for whom it is impossible to give informed information.
- Pregnant, parturient or breastfeeding women.